HR 6832
To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.
Official facts
These fields are copied from the synchronized official record.
Referred to the Subcommittee on Health.
Lifecycle
This section is generated by FederalStateData from accepted bill actions and remains labeled as derived.
Referred to the Subcommittee on Health.
Sponsors and cosponsors
| Member | Party | Role | Sources |
|---|---|---|---|
| Michael Cloud | Republican Party | PRIMARY | |
| Andy Biggs | Republican Party | COSPONSOR | |
| Byron Donalds | Republican Party | COSPONSOR | |
| Daniel Webster | Republican Party | COSPONSOR | |
| Mary E. Miller | Republican Party | COSPONSOR | |
| Mo Brooks | Republican Party | COSPONSOR | |
| Thomas P. Tiffany | Republican Party | COSPONSOR |
Actions
Feb 28, 2022 · Committee
Referred to the Subcommittee on Health.
Feb 25, 2022 · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 25, 2022 · IntroReferral
Introduced in House
Amendments
Committees
| Committee | Chamber | Relationship | Source |
|---|---|---|---|
| Energy and Commerce Committeehsif00 | HOUSE | REFERRED | Official relationship ↗ |
| Financial Services Committeehsba00 | HOUSE | REFERRED | Official relationship ↗ |